Skip to Content

Notice

Agency Information Collection Activities: Submission for OMB Review; Comment Request

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (301) 443-7978.

Opioid Drugs in Maintenance and Detoxification Treatment of Opioid Addiction—42 CFR part 8 (OMB No. 0930-0206; Revision)—This regulation establishes a certification program managed by SAMHSA's Center for Substance Abuse Treatment (CSAT). The regulation requires that Opioid Treatment Programs (OTPs) be certified. “Certification” is the process by which SAMHSA determines that an OTP is qualified to provide opioid treatment under the Federal opioid treatment standards established by the Secretary of Health and Human Services. To become certified, an OTP must be accredited by a SAMHSA-approved accreditation body. The regulation also provides standards for such services as individualized treatment planning, increased medical supervision, and assessment of patient outcomes. This submission seeks continued approval of the information collection requirements in the regulation and of the forms used in implementing the regulation.

SAMHSA currently has approval for the Application for Certification to Use Opioid Drugs in a Treatment Program Under 42 CFR 8.11 (Form SMA-162); the Application for Approval as Accreditation Body Under 42 CFR 8.3(b) (Form SMA-163); and the Exception Request and Record of Justification Under 42 CFR 8.12 (Form SMA-168), which may be used on a voluntary basis by physicians when there is a patient care situation in which the physician must make a treatment decision that differs from the treatment regimen required by the regulation. Form SMA-168 is a simplified, standardized form to facilitate the documentation, request, and approval process for exceptions. Minor changes are being made to Form SMA-162 to account for newly approved opioid treatment drugs, to provide structures space on the form for required information and to make it more compatible with electronic submission.

The tables that follow summarize the annual reporting burden associated with the regulation, including burden associated with the forms.

Estimated Annual Reporting Requirement Burden for Accreditation Bodies

42 CFR citationPurposeNumber of respondentsResponses/ respondentsHours/ responseTotal hours
8.3(b)(1-11)Initial approval (SMA-163116.06.0
8.3(c)Renewal of approval (SMA-163)211.02.0
8.3(e)Relinquishment notification110.50.5
8.3(f)(2)Non-renewal notification to accredited OTP's1900.19.0
8.4(b)(1)(ii)Notification to SAMHSA for seriously noncompliant programs221.04.0
8.4(b)(1)(iii)Notification to OTP for serious noncompliance2101.020.0
8.4(d)(1)General documents and information to SAMHSA upon request650.515.0
8.4(d)(2)Accreditation survey to SAMHSA upon request6750.029.0
8.4(d)(3)List of surveys, surveyors to SAMHSA upon request660.27.2
8.4(d)(4)Report of less than full accreditation to SAMHSA650.515.0
8.4(d)(5)Summaries of Inspections6500.5150.0
8.4(e)Notifications of Complaints660.518.0
8.6(a)(2) and (b)(3)Revocation notification to Accredited OTP's11850.355.5
8.6(b)Submission of 90-day Corrective plan to SAMHSA111010.0
8.6(b)(1)Notification to accredited OTP's of Probationary Status11850.355.0
Total7376.2

Estimated Annual Reporting Requirement Burden for Opioid Treatment Programs

42 CFR citationPurposeNumber of respondentsResponses/ respondentsHours/ responseTotal hours
8.11(b)New programs approval (SMA-162)7511.50112.50
8.11(b)Renewal of approval (SMA-162)370.0011.00370
Start Printed Page 45262
8.11(b)Relocation of Program (SMA-162)3511.1740.95
8.11(d)Application for transitional certification (SMA-162)*0000
8.11(e)(1)Application for provisional certification751175.00
8.11(e)(2)Application for extension of provisional certification301.257.50
8.11(f)(5)Notification of sponsor or medical director change (SMA-162)601.16.00
8.11(g)(2)Documentation to SAMHSA for interim maintenance1111.00
8.11(h)Request to SAMHSA for Exemption from 8.11 and 18.12 (SMA-168)1,1107.1521181.04
8.11(i)(1)Notification to SAMHSA Before Establishing Medication Units (SMA-162)101.252.5
8.12(j)(2)Notification to State Health Officer When Patient Begins Interim Maintenance120.336.6
8.24Contents of Appellant Request for Review of Suspension21.25.50
8.25(a)Informal Review Request211.002.00
8.26(a)Appellant's Review File and Written Statement215.0010.00
8.28(a)Appellant's Request for Expedited Review211.002.00
8.28(c)Appellant Review File and Written Statement215.0010.00
Total1,1001827.6
* This is a one-time requirement that was fully met during the first three years of approval for the final rule.

SAMHSA believes that the recordkeeping requirements in the regulation are customary and usual practices within the medical and rehabilitative communities and has not calculated a response burden for them. The recordkeeping requirements set forth in 42 CFR 8.4, 8.11 and 8.12 include maintenance of the following: 5-year retention by accreditation bodies of certain records pertaining to accreditation; documentation by an OTP of the following: a patient's medical examination when admitted to treatment, a patient's history, a treatment plan, any prenatal support provided the patient, justification of unusually large initial doses, changes in a patient's dosage schedule, justification of unusually large daily doses, the rationale for decreasing a patient's clinic attendance, and documentation of physiologic dependence.

The rule also includes requirements that OTPs and accreditation organizations disclose information. For example, 42 CFR 8.12(e)(1) requires that a physician explain the facts concerning the use of opioid drug treatment to each patient. This type of disclosure is considered to be consistent with the common medical practice and is not considered an additional burden. Further, the rule requires, under 8.4(i)(1) that accreditation organizations shall make public their fee structure; this type of disclosure is standard business practice and is not considered a burden.

Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to: Allison Herron Eydt, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503; due to potential delays in OMB's receipt and processing of mail sent through the U.S. Postal Service, respondents are encouraged to submit comments by fax to: 202-395-6974.

Start Signature

Dated: July 25, 2003.

Anna Marsh,

Acting Executive Officer, SAMHSA.

End Signature End Preamble

[FR Doc. 03-19586 Filed 7-31-03; 8:45 am]

BILLING CODE 4162-20-P